Avoid common mistakes on your manuscript.
X-linked agammaglobulinemia (XLA) is usually presented with clinical manifestations of bacterial respiratory and/or gastrointestinal infections below the age of 1 year, when the maternal IgG through placenta disappears from the circulation of the baby. Here, we describe an infant with XLA, who presented with interstitial pneumonia suggestive of Pneumocystis jiroveci (formerly Pneumocystis carinii) infection.
1 Patient report
A 3-month-old boy was admitted to Mie Hospital because of a long-standing cough, tachypnea and cyanosis. Physical examination showed a weight of 5.8 kg, temperature of 36.3°C, pulse of 170/min, respiration rate of 68/min, oxygen saturation on room air of 60%, respiratory retraction, and abnormal lung auscultation, but there was no lymphadenopathy. Chest radiology showed alveo-interstitial pneumonia (Fig. 1a), and chest computed tomography demonstrated diffuse ground-glass opacities (Fig. 1b). Laboratory tests showed a white blood count of 15,500/µl with 31.9% neutrophils and 54.4% lymphocytes, along with C-reactive protein of 0.02 mg/dl. The patient needed supplement oxygen, but did not require mechanical ventilation. He was first suspected of viral or Chlamydia pneumonia, and clarythromycin was administered but there was no improvement. Serum IgM against Chlamydia trachomatis and cytomegalovirus were negative. The patient’s serum IgG, IgA and IgM levels were 108, 0 and 15 mg/dl, respectively, and the peripheral B cells were absent, suggesting an XLA despite the lack of a family history. With parental consent, the patient was diagnosed as having XLA based on a missense mutation (Arg28His) in the Bruton’s tyrosine kinase (BTK) gene. The responses to phytohemagglutinin and concanavalin A are 56900 and 30900 cpm (control 141 cpm), respectively. Although T cell number and function were normal, he was suspected to have Pneumocystis jiroveci pneumonia. An elevated level of β-d glucan of >300 pg/ml (normal value <20) and KL-6 of 8750 U/ml (normal value, <500), suggested interstitial pneumonia caused by Pneumocystis jiroveci; however, polymerase chain reaction of sputum showed a negative result of Pneumocystis jiroveci. This may have been due to inadequate collection of sputum. He was treated with administration of sulfamethoxazole-trimethoprim (ST) and intravenous immunoglobulin (IVIG), with clinical improvement. The patient is currently well with IVIG replacement therapy and prophylactic administration of ST (Fig. 2).
2 Discussion
Interstitial pneumonia is caused by many organisms such as cytomegalovirus, adenovirus, fungus, and Pneumocystis jiroveci. An infant with interstitial pneumonia may be suspected of having an immunocompromised host with T cell deficiency, although there may have been Pneumocystis jiroveci pneumonia even in immunocompetent infants [1, 2]. XLA is a humoral immunodeficiency resulting from a block in early B cell development, and it is clinically characterized by recurrent bacterial infections [3]. Although XLA patients sometimes demonstrate enteroviral infections, they usually show a normal response to viral and fungus infections because of normal T cell functions. However, 3 XLA patients with Pneumocystis jiroveci pneumonia have been reported [4–6]. One of these three was an adult receiving immunosuppressive therapy, but 2 patients were infants as in our case. It has recently been reported that Toll-like receptor signaling is impaired in XLA [7, 8] and that may be associated with the development of Pneumocystis jiroveci infection in XLA patients. Prophylactic administration of ST as well as IVIG replacement therapy would be recommended for the treatment of XLA patients.
References
Stagno S, Pifer LL, Hughes WT, Brasfield DM, Tiller RE. Pneumocystis carinii pneumonitis in young immunocompetent infants. Pediatrics. 1980;66:56–62.
Brasfield DM, Stagno S, Whitley RJ, Cloud G, Cassell G, Tiller RE. Infant pneumonitis associated with cytomegalovirus, Chlamydia, Pneumocystis, and Ureaplasma: follow-up. Pediatrics. 1987;79:76–83.
Conley ME, Broides A, Hernandez-Trujillo V, Howard V, Kanegane H, Miyawaki T, et al. Genetic analysis of patients with defects in early B-cell development. Immunol Rev. 2005;203:216–34. doi:10.1111/j.0105-2896.2005.00233.x.
Alibrahim A, Lepore M, Lierl M, Fillipovich A, Assa’ad A. Pneumocystis carinii pneumonia in an infant with X-linked agammaglobulinemia. J Allergy Clin Immunol. 1998;101:552–3. doi:10.1016/S0091-6749(98)70363-X.
Gaspar HB, Ferrando M, Caragol I, et al. Kinase mutation Btk results in atypical X-linked agammaglobulinemia phenotype. Clin Exp Immunol. 2000;120:346–50. doi:10.1046/j.1365-2249.2000.01230.x.
Sirianni MC, Atzori C, De Santis W, et al. A case of Pneumocystis jiroveci pneumonia in X-linked agammaglobulinemia treated with immunosuppressive therapy: a lesson for immunologists. Int Arch Allergy Immunol. 2005;140:82–8. doi:10.1159/000092139.
Sochorová K, Horáth R, Rozková D, et al. Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia. Blood. 2007;109:253–2556. doi:10.1182/blood-2006-07-037960.
Taneichi H, Kanegane H, Sira MM, et al. Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia. Clin Immunol. 2008;126:148–54. doi:10.1016/j.clim.2007.10.005.
Acknowledgments
This study was partly supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Ministry of Health, Labour and Welfare of Japan.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kanegane, H., Nakano, T., Shimono, Y. et al. Pneumocystis jiroveci pneumonia as an atypical presentation of X-linked agammaglobulinemia. Int J Hematol 89, 716–717 (2009). https://doi.org/10.1007/s12185-009-0322-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-009-0322-5